Aveo Oncology Wins FDA Approval for Kidney Cancer Drug
- Posted by ISPE Boston
- On April 8, 2021
Aveo Oncology has announced FDA approval for Fotivda (tivozanib) for the treatment of adults with renal cell carcinoma (RCC) who meet certain treatment guidelines. Fotivda is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and was approved in August 2017 in the European Union and other EUSA countries. According to the American Cancer Society, renal cell […]
Read More